{"filings":[{"id":2026758,"accession_number":"0001493152-26-035859","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2026-08-03T21:20:19+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ainos Q2 2026: no financials; AI Nose deployments expand; $2.1M commercial arrangement","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["No revenue or EPS figures provided in the press release; only qualitative business update.","AI Nose deployments advanced under previously announced $2.1M commercial arrangement in backend semiconductor manufacturing.","Since Dec 2025, AI Nose accumulated ~613 million industrial smell data records, primarily from semiconductor environments.","Pilot programs expanded in front-end semiconductor, industrial infrastructure, healthcare, and robotics environments.","CFO expects broader revenue generation opportunities in second half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":313.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1580797,"accession_number":"0001493152-26-032835","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2026-07-10T20:10:33+00:00","items":["4.01","9.01"],"status":"ready","headline":"Ainos dismisses YCM CPA as auditor, engages DLEE Accountancy as new independent auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed YCM CPA INC. as independent registered public accounting firm on July 9, 2026, following expiration of engagement.","Engaged DLEE Accountancy, Inc. as new independent registered public accounting firm on same day.","No disagreements or reportable events with YCM during most recent fiscal year and through dismissal.","Company requested YCM to furnish a letter to SEC regarding agreement with statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1556036,"accession_number":"0001493152-26-032729","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2026-07-09T21:29:09+00:00","items":["2.03","9.01"],"status":"ready","headline":"Ainos enters NT$62M (US$1.94M) unsecured credit facility with CTBC Bank at 2.5% p.a., maturing Sept 30, 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Credit facility of NT$62,000,000 (approx US$1,937,800) from CTBC Bank.","Interest rate of 2.5% per annum; facility is unsecured and matures on September 30, 2026.","Proceeds for general corporate purposes; contains customary events of default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":69086,"accession_number":"0001493152-26-022751","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2026-05-13T20:30:29+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ainos Q1 2026: operating expenses down 30% to $2.28M, secures $2.8M financing, progresses AI Nose deployments","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating expenses declined ~30% YoY to approximately $2.28 million for Q1 2026.","Strengthened balance sheet with NT$90 million (~$2.8 million) financing arrangement during the quarter.","Continued deployment under $2.1M commercial arrangement in backend semiconductor environments targeting ~1,400 AI Nose systems.","Initiated pilot and validation activities in front-end semiconductor environments and expanded distribution partnership.","Expanded AI Nose into healthcare infrastructure settings including hospital utility, HVAC, and MRI environments."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":161.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100260,"accession_number":"0001493152-26-013578","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ainos FY2025 revenue up 499%, gross margin 82.9%; AI Nose deployments scaling in semiconductor","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue up ~499% YoY; gross margin improved to 82.9% from a gross loss in 2024.","OpEx (excl. share-based comp & D&A) decreased 9% YoY; total OpEx increased ~2%.","Raised NT$90M (~$2.82M) post-year-end 2026 for liquidity.","AI Nose deployments: ~200 systems in wafer fabs (Q1 2026); ~1,400 systems under $2.1M three-year deal.","Potential scale to 20,000 systems subject to validation and contractual conversion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100259,"accession_number":"0001493152-26-000517","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ainos grants distribution rights to Trusval Technology for AI Nose products","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three-year distribution agreement with Trusval Technology Co. Ltd. for AINOS AI Nose and related products.","Trusval gets one-year exclusive distribution rights for sales to certain clients.","No financial terms or revenue projections disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100258,"accession_number":"0001493152-26-000271","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Ainos outlines SmellTech platform strategy to digitize scent for AI; 2026 focus on semiconductor manufacturing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proprietary AI Nose hardware generates repeatable scent data for large-scale AI training.","Wholly owned ScentAI subsidiary developing Smell Language Model (SLM) for classification and cross-environment learning.","Company plans 2026 transition to scaled deployment, targeting advanced semiconductor manufacturing and robotics.","Structural separation: Ainos handles hardware and certifications; ScentAI handles AI model development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116592,"accession_number":"0001493152-25-029794","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Ainos issues 1.16M shares of common stock to wholly owned subsidiary ScentAI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,160,000 shares of AIMD common stock to ScentAI Inc. in exchange for 116,000,000 ScentAI shares.","The issued shares have no voting power while held by the wholly owned subsidiary.","Post-issuance, total outstanding common shares are 6,982,675 as of December 30, 2025.","Securities issued in reliance on Section 4(a)(2) exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116591,"accession_number":"0001493152-25-022311","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","5.07","9.01"],"status":"ready","headline":"Ainos Q3 2025 results omit financials; focuses on AI Nose partnerships and patents","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["No net revenue or EPS disclosed in Q3 2025 press release; SG&A down 22% YoY, total opex down 8%.","Strategic partnerships with NEXCOM (industrial edge AI) and Topco Scientific (semiconductor distribution) announced.","Received 7 new patents in Europe, Germany, Taiwan, China; now holds 123 active patents.","Launched first commercial portable AI Nose module for industrial and healthcare use in August 2025.","At annual meeting, all 7 director nominees elected; auditor YCM CPA INC. ratified; 950K share award approved."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":113037.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116590,"accession_number":"0001493152-25-018460","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ainos extends patent license fee term to two years at $50,000/month with TCNT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fourth addendum to Product Development Agreement with Taiwan Carbon Nano Technology (TCNT) signed Oct 15, 2025.","Fee for exclusive patent use remains $50,000/month plus 5% sales tax, now for two years starting Oct 16, 2025.","Previous addendum covered one year from Oct 16, 2024; extension adds another year to the term.","Parties may negotiate payment terms and subsequent licensing methods after the two-year period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133041,"accession_number":"0001493152-25-012781","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ainos files prospectus supplement for $874,496 ATM stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company filed prospectus supplement on Sept 5, 2025 to sell up to $874,496 in common stock via ATM agreement with H.C. Wainwright.","Prior sales under the same ATM totalled approximately $1,840,337, exhausting the earlier $1,840,350 limit.","Use of proceeds is not stated in the filing; offering will be made from time to time through the placement agent.","Legal opinion of Lucosky Brookman LLP on share validity was filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133040,"accession_number":"0001641172-25-023515","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ainos Q2 2025 results highlight $2.1M AI Nose order and commercial momentum","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Secured $2.1M three-year subscription order from ASEH for AI Nose in semiconductor manufacturing.","Launched pilot deployments of AI Nose-equipped ugo robots at seven industrial sites in Japan.","Formed five-year distribution partnership with Solomon and alliance with Kenmec for smart factory.","CFO reported first-half operating cash outflows narrowed 26% YoY; gross profitability in Q2 2025.","Completed 1-for-5 reverse split to regain Nasdaq compliance; net $719K from ATM facility."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":110870.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133039,"accession_number":"0001493152-25-011679","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ainos secures $2.1M order with ASE for AI Nose deployment in semiconductor manufacturing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three-year subscription order valued at $2.1M from ASE Technology Holding, the world's largest semiconductor assembly and test provider.","Deployment of 1,400 AI Nose units across ASEH's three major sites in Taiwan: Kaohsiung, Zhongli, and SPIL.","First revenue-generating order for AI Nose in industrial market; follows first revenue in senior care in Q1 2025.","Next pilot deployments planned at seven sites in Japan with robotics partner ugo, and multi-site rollouts with Kenmec and Solomon in Taiwan.","Ainos positions SmellTech-as-a-Service model to enhance smart manufacturing with AI-powered scent intelligence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133038,"accession_number":"0001493152-25-011520","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Ainos appoints new auditor YCM CPA after KCCW resignation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KCCW resigned as independent auditor on July 30, 2025, citing exit from public company audit practice.","Audit committee engaged YCM CPA Inc. as new independent registered public accounting firm on July 31, 2025.","No disagreements or reportable events occurred with KCCW during past fiscal year or through dismissal.","Company had not consulted YCM on any accounting, auditing, or financial reporting issue prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133037,"accession_number":"0001493152-25-011263","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ainos regains Nasdaq compliance; sets 90-day AI Nose scale plan with 412% Q1 revenue jump","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq confirmed compliance on July 15, 2025; closing bid price >= $1.00 for 10 consecutive days.","Q1 2025 revenue up 412% YoY driven by AI Nose sales for senior care program.","Strategic partnership with ASEH targets up to 15,000 AI Nose units; pilot of ~1,400 units underway.","SLM now >90% accurate on everyday scents; senior care accuracy improved to ~85% from ~80%.","Near-term priorities include SaaS model, humanoid robot integration, and Asia/Europe partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133036,"accession_number":"0001641172-25-017366","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Ainos effects 1-for-5 reverse stock split effective June 30, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:5 ratio effective 5:01 a.m. Central on June 30, 2025.","No fractional shares issued; cash paid based on June 27 closing price.","Outstanding options and warrants adjusted proportionally; new CUSIP 00902F402.","Common stock (AIMD) began trading on split-adjusted basis at Nasdaq market open."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149618,"accession_number":"0001641172-25-016226","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ainos forms strategic partnership with Kenmec to deploy AI Nose in smart factories","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Legally binding strategic partnership announced June 24, 2025.","Kenmec receives commercial license for AI Nose; Kentec Inc. appointed manufacturing partner.","Co-exhibit at Automation Taipei 2025 in August targeting robotics, HVAC, logistics, medical sectors.","Partnership builds on prior AI Nose deployments in Japan eldercare and 56 ASE semiconductor factories."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149617,"accession_number":"0001641172-25-009580","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ainos Q1 revenue up 412% to $106K; gross profit swings to positive; partnerships in robotics and semiconductors","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue up 412% YoY to $106,207; gross profit of $87,974 vs prior-year gross loss of $6,025.","Cost of revenue down 32% YoY to $18,233, driving gross margin improvement.","AI Nose deployed in semiconductor manufacturing via ASE partnership; olfactory module installed on ugo robots.","VELDONA secured TFDA approval for HIV oral warts trial and IRB clearance for Sjögren's syndrome trial.","No net income or EPS disclosed; share-based compensation increased SG&A expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":106207.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168679,"accession_number":"0001493152-25-010373","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ainos extends maturity of $1M convertible note to May 13, 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Original $1,000,000 convertible note issued March 13, 2023 with 6% compounded interest.","Conversion price was $1.50, adjusted to $7.50 after 1-for-5 reverse stock split in Dec 2023.","Amendment dated March 12, 2025 extends maturity date to May 13, 2025.","Note holder is Li-Kuo Lee; terms otherwise unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168678,"accession_number":"0001493152-25-009851","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ainos signs MOU with ASE to deploy AI Nose for semiconductor VOC detection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ainos (AIMD) and Advanced Semiconductor Engineering (ASE) signed a legally binding MOU to integrate AI Nose into ASE's 46 fully automated factories.","AI Nose successfully identified 22 VOCs with nearly 80% accuracy in Japanese semiconductor facilities.","Partnership aims to optimize manufacturing, enable predictive maintenance, and enhance ESG compliance via real-time air chemistry insights.","Ainos recently partnered with ugo, Inc. to develop the first robot with a sense of smell, expanding AI Nose from healthcare to industrial automation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168677,"accession_number":"0001493152-25-009745","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ainos amends convertible note: maturity extended to 2027, conversion price floor lowered to $4.50","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity extended from ~March 2025 to March 12, 2027; principal $2M at 6% compounded interest unchanged.","Conversion price changed from fixed $7.50 to lower of $7.50 or higher of 30-day avg closing price and $4.50.","Amendment with ASE Test, Inc., a shareholder of Ainos' controlling shareholder (Cayman entity).","Note remains convertible at holder's election; new formula may reduce conversion price from $7.50."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168676,"accession_number":"0001493152-25-009578","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ainos reports FY2024 revenue $20,729, net loss $14.9M; AI Nose and VELDONA progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell 83% YoY to $20,729; cost of revenues $52,595; gross loss narrowed to $31,866.","Net loss attributable to common shareholders $14.86M vs $13.77M in FY2023.","Cash and equivalents $3.89M as of Dec 31, 2024, up from $1.89M a year ago.","R&D expenses rose to $8.4M (including share-based comp); SG&A decreased to $5.4M.","Key milestones: AI Nose Flora second-gen clinical studies H1 2025; VELDONA Japan patent and Taiwan Tanabe partnership; IRB approval for Sjögren's trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168675,"accession_number":"0001493152-25-009222","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ainos partners with ugo to integrate AI Nose into robots for scent detection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ainos (AIMD) and ugo, Japan's largest service robot firm, to develop first smell-enabled robot.","AI Nose technology detects VOCs with ~80% accuracy in semiconductor facilities; to be embedded in ugo robots.","Applications include industrial safety, public security, environmental monitoring, and healthcare.","Revenue models: technology licensing, RaaS subscriptions, cloud analytics, and maintenance services.","Development roadmap includes prototyping, pilot deployments, AI optimization, and global commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185786,"accession_number":"0001493152-24-048611","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ainos signs non-binding MOU with Taiwan Tanabe for VELDONA manufacturing and Taiwan market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-binding MOU with Taiwan Tanabe Seiyaku (Mitsubishi Tanabe subsidiary) for exclusive marketing, manufacturing, and marketing authorization of VELDONA in Taiwan.","Exclusive right of first negotiation for 3 months from Nov 27, 2024, extendable by 3 months with mutual written notice.","License fees, milestones, and profit-sharing to be agreed in future definitive agreement, contingent on VELDONA NDA approval in Taiwan.","VELDONA is low-dose oral interferon-alpha for Sjögren's syndrome; prior studies showed symptom alleviation and good safety profile.","Ainos believes partnership will accelerate global market entry; Sjögren's syndrome market projected billions in 5 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185785,"accession_number":"0001493152-24-042062","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ainos adds exclusive patent rights and co-development of nitrogen-oxygen separation machine with TCNT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Third Addendum to Product Development Agreement adds nitrogen-oxygen separation machine for medical oxygen and wound healing.","TCNT grants Ainos exclusive sales rights and full patent authorization for the new machine.","Exclusive patent use fee set at $50,000/month plus 5% sales tax for one year starting October 16, 2024.","TCNT controls ~62.9% of Ainos voting power as of October 17, 2024.","Co-development scope expanded to include VELDONA drug pre-processing and manufacturing development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185784,"accession_number":"0001493152-24-039026","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ainos shareholders ratify auditor, approve 2M share special stock award at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ratification of KCCW Accountancy Corp. as auditor approved with 5,062,909 for, 52,319 against.","Reservation of up to 2 million shares for special stock awards approved with 3,804,071 for, 166,746 against.","Annual meeting held September 27, 2024; quorum of 63.82% of outstanding shares represented.","Broker non-votes totaled 1,157,648 on the stock award proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202356,"accession_number":"0001493152-24-030970","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Ainos issues 5.5M shares to TCNT for exclusive patent license; TCNT voting power to increase to 63.2%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 5.5M shares to TCNT for exclusive, irrevocable, perpetual license of gas-sensor and medical-device patents.","TCNT's voting power rises from approx. 38% to 63.2% post-issuance; TCNT to enter voting agreement with Ainos KY.","Fully prepaid $1.67M Lind convertible note with $1.44M cash and 382,384 shares at $0.588/share.","Lawrence K. Lin stepped down as EVP of Operations effective Aug 9, 2024; no longer executive officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202355,"accession_number":"0001493152-24-030263","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ainos Q2 2024 net loss widens to $3.2M; revenues nil; FCGS trial begins","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues nil vs $28,555 YoY as COVID-19 test kit sales ceased; net loss $3,195,022 vs $2,349,727.","Cash $8,014,098 at June 30, 2024, after $9M convertible note in May and prepayment of senior secured note.","Enrolled first subject for VELDONA-based FCGS clinical study in July; 30-subject trial aims for Q1 2025 completion.","Next-Gen Ainos Flora VOC POCT with NVIDIA CUDA targets Q3 design completion, Q4 clinical trial kickoff.","Operating expenses rose to $3,023,636 from $2,289,336 YoY, driven by co-research, staff, and stock-based compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":20729.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202354,"accession_number":"0001493152-24-028511","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ainos receives Nasdaq deficiency notice for bid price below $1; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Ainos that its common stock bid price closed below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until January 13, 2025, to regain compliance by closing at $1.00 or more for 10 consecutive business days.","If not cured, Ainos may be eligible for an additional 180-day period if it meets other initial listing standards and notifies Nasdaq of intent to cure.","No immediate effect on listing; shares continue trading under AIMD and AIMDW on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202353,"accession_number":"0001493152-24-027093","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ainos extends patent license with TCNT for three months at $95k/month","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Addendum extends non-exclusive patent use for VOC/POCT tech from July to Sept 2024.","Monthly fee of US$95,000 plus 5% sales tax for the three-month extension.","Co-development fee of NT$5 million (≈USD$161,000) paid for five-year period starting 2024.","TCNT holds ~39% voting power of Ainos via a Cayman entity; related party transaction.","Scope includes VOC diagnostics, AI Nose, POCT, VELDONA drug processing, and more."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218474,"accession_number":"0001493152-24-024514","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Ainos reports 75-case clinical trial progress for Ainos Flora; next-gen device with NVIDIA CUDA targeting Q3/Q4","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Clinical trials for AI Nose-powered Ainos Flora achieved 75 meaningful case results, validating AI algorithm model.","Next-gen Ainos Flora will leverage NVIDIA CUDA for accelerated deep learning; design completion expected Q3, clinical trials Q4.","Second-generation device targets at-home testing for viral infections, expanding beyond bacterial/fungal/STI detection.","Board approved amended bylaws reducing stockholder meeting quorum to one-third and adding advance notice procedures.","STI testing market projected US$256B by 2028; POCT accounts for 31%, presenting opportunity for telehealth-friendly rapid testing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218473,"accession_number":"0001493152-24-018884","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ainos Q1 revenue down 58% YoY to $20.7K; net loss widens to $3.3M; secures $9M convertible note","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $20,729 in Q1 2024, down 58% from $49,164 in Q1 2023, due to pivot from COVID-19 test kits.","Net loss attributable to common stockholders was $3.3M, compared to $2.5M in prior year.","Cash and cash equivalents $1.03M as of Mar 31, 2024, down from $1.89M at Dec 31, 2023.","Raised $9M convertible note post-quarter (6% interest, convertible at $4.50/sh) from existing shareholder.","Submitted clinical hold response to FDA for VELDONA Phase II trial for mild COVID-19."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":20729.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218472,"accession_number":"0001493152-24-017831","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Ainos issues $9M convertible note to ASE Test, with warrant for 500k shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$9,000,000 convertible note, 6% compound interest, matures May 3, 2027.","Conversion at $4.50 per share, subject to anti-dilution adjustments.","Warrant for 500,000 shares at $4.50, exercisable after 6-month lock-up.","Voting agreement gives Ainos KY control over ASE Test's shares, restricts transfers for 5 years.","Proceeds use not specified; transaction exempt under Regulation S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238381,"accession_number":"0001654954-24-003372","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ainos appoints Christopher Hsin-Liang Lee as CFO, effective March 18, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mr. Lee named CFO; over 25 years of accounting/finance experience including 10 years as CFO of a Nasdaq-listed company.","Basic monthly salary of NT$200,000 plus year-end bonus equal to two months' base salary.","Employment agreement includes standard non-compete (24 months) and confidentiality provisions governed by Taiwan law.","No family relationships or reportable transactions between Mr. Lee and any director/officer of the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238380,"accession_number":"0001654954-24-003224","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Meng-Lin Sung resigns effective March 13, 2024; no replacement named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Meng-Lin Sung resigned as CFO of Ainos, Inc. effective March 13, 2024.","Resignation not related to any disagreement with operations, accounting policies or practices.","No successor has been appointed as of the filing date; CEO Chun-Hsien Tsai signed the report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238379,"accession_number":"0001654954-24-002898","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ainos reports FY2023 revenue drop to $122K; net loss $13.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell 97% to $122,112 from $3.52M in 2022, driven by COVID-19 test kit sales decline.","Gross loss of $253,733 vs positive gross profit of $1.4M a year earlier; net loss $13.77M vs $14.01M.","Cash and cash equivalents $1.89M at Dec 31, 2023, nearly flat from $1.85M at Dec 31, 2022.","R&D expenses rose to $7.32M; SG&A fell to $5.64M on lower share-based compensation.","Strategic pivot: advancing VELDONA Phase III, AI Nose VOC platform with NISD & Inabata, and pet supplement sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238378,"accession_number":"0001654954-24-001299","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ainos submits clinical hold complete response to FDA for VELDONA Phase 2 COVID-19 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Submitted clinical hold complete response to FDA for Phase 2 trial of low-dose oral IFN-alpha VELDONA for mild COVID-19.","Phase 2 multicenter randomized study expected in Taiwan in Q3 2024 if approved.","Updated CMC and stability data show VELDONA can exceed minimum shelf life for biologicals.","Plans additional IND applications in H2 2024 for oral warts (orphan drug) and Sjögren's syndrome.","Low-dose oral VELDONA safety demonstrated in ~6,000 subjects across 68 clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238377,"accession_number":"0001654954-24-000933","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Ainos secures $1.75M additional funding via amended convertible note with Lind Global","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.75M total, $875k funded at closing; $875k subject to registration statement conditions.","Note maturity extended to March 28, 2025, with optional extension; conversion price $7.50/share.","Lind receives warrant for 1,021,400 shares at $2.16/share; placement agents get warrants and 7% cash fee.","Proceeds to advance VELDONA IND preparation and AI Nose VOC platform with NISD and Inabata.","Maxim Group (lead) and Brookline Capital Markets acted as placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238376,"accession_number":"0001654954-24-000521","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-01-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ainos enters addendum to product development agreement with affiliate TCNT; defines co-development products and fees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Addendum specifies co-development products: VOC diagnostics, AI Nose, POCT, VELDONA drug processing, lateral flow diagnostics.","Ainos to pay TCNT total fee of NT$5M (~USD$161k) over five years starting 2024.","Non-exclusive patent license for VOC and POCT: US$95k/month (plus 5% tax) for initial six months from Jan 2024.","TCNT provides facilities, equipment, mass production tech and ISO9001/13485 management; parts, raw materials, utilities excluded.","Original agreement effective Aug 2021 to Jul 2026; addendum ratified by audit committee on Jan 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238375,"accession_number":"0001654954-24-000083","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ainos regains compliance with Nasdaq Rule 5550(a)(2) after bid price recovers","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Ainos on Dec 29, 2023 that it regained compliance with the minimum bid price requirement.","Compliance achieved after closing bid price was $1.00 or greater for 10 consecutive business days (Dec 14-28, 2023).","The company had previously been notified of deficiency on Jan 5, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255873,"accession_number":"0001654954-23-015938","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ainos Chief Legal Counsel and Corporate Secretary John Junyong Lee resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Junyong Lee resigned as Chief Legal Counsel and Corporate Secretary effective December 20, 2023.","Resignation not related to any disagreement with company's operations, policies, or practices.","No replacement named; CEO Chun-Hsien Tsai signed the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255872,"accession_number":"0001654954-23-015506","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Ainos announces 1-for-5 reverse stock split effective Dec 14, 2023; increases authorized preferred shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-5 ratio effective Dec 14, 2023; fractional shares paid in cash.","Authorized preferred shares increased from 10M to 50M; may be issued in series.","Outstanding options and warrants adjusted proportionally; new CUSIP 00902F303.","Common stock begins trading on split-adjusted basis on Nasdaq as of Dec 14, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255871,"accession_number":"0001654954-23-015436","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ainos implements 1-for-5 reverse stock split effective December 14, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1:5; new shares trade Dec 14 under same ticker AIMD with new CUSIP 00902F303.","Post-split outstanding shares ~4,677,898; authorized shares and par value unchanged.","No fractional shares issued; holders of fractional interests will receive cash in lieu.","Outstanding options adjusted to ~7,333, warrants to ~664,730 proportionally.","Instructions from transfer agent Equiniti Trust Company for certificate exchange."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255870,"accession_number":"0001654954-23-015364","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Ainos stockholders ratify auditor, approve say-on-pay, and opt for triennial advisory votes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ratified KCCW Accountancy Corp. as auditor for FY2023: 78.15% FOR, 0.58% AGAINST.","Approved advisory say-on-pay for named executive officers: 70.70% FOR, 0.22% AGAINST.","Advisory frequency vote favored every three years (67.58%) over one year (3.29%) or two years (0.04%).","Board determined to continue triennial advisory votes on executive compensation until next frequency vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255869,"accession_number":"0001654954-23-014742","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2023-11-24T23:59:59+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"Ainos issues 3,000,000 shares of common stock as Special Stock Awards to officers and directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3M shares issued unregistered under Section 4(a)(2)/Reg D to nine insiders.","CEO Chun-Hsien Tsai receives 880,000 total shares (250k as Chair, 630k as CEO).","CFO Meng Lin Sung receives 300,000 shares; other directors each get 250,000 shares.","Awards include 10,000 shares to EVP Operations Lawrence K Lin and 10,000 to Chief Legal Counsel Jun Lee.","Shares are not registered under Securities Act; reliance on exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255868,"accession_number":"0001654954-23-014166","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ainos Q3 2023 revenue drops 98.6% to $24.5K; net loss narrows to $3.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell to $24,489 from $1,757,774 in Q3 2022 due to COVID-19 test kit demand decline.","Gross profit turned negative ($63,384) vs positive $581,742 YoY on lower sales and inventory loss.","Net loss narrowed to $2.97M from $7.82M YoY, helped by lower operating expenses.","Cash and equivalents $2.37M as of Sept 30, 2023; company secured $3M of planned $10M private placement.","VELDONA Pet launched in Taiwan (300k units shipped); FDA orphan drug designation for VELDONA for oral warts."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":102208.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273290,"accession_number":"0001654954-23-012402","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Ainos enters $10M private placement with Lind Global; initial $3M tranche funded","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial closing: $2M funded now; remaining $1M subject to shareholder approval and SEC registration.","Senior secured convertible note (18-month maturity) convertible at $1.50/share; warrants at $0.90/share.","Proceeds to fund clinical trials, commercial product launch, and working capital.","Additional tranches up to $7M possible upon mutual agreement and satisfaction of conditions.","Maxim Group and Brookline Capital Markets acted as placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273289,"accession_number":"0001654954-23-011112","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2023-08-22T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Ainos extends two promissory notes: $300K KY Note to March 2025, $42K i2China Note to Sept 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["KY Note extended to March 31, 2025; unpaid principal $300K plus accrued interest at 1.85%.","i2China Note extended to Sept 1, 2024; unpaid principal $42K plus accrued interest at 1.85%.","Company retains right to prepay principal/interest with equitable adjustment.","Original i2China Note matured Jan 1, 2021; extension avoids default on past-due obligation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273288,"accession_number":"0001654954-23-010608","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ainos Q2 revenue collapses to $28.6K; net loss widens to $2.35M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue dropped ~95% YoY to $28,555 from $636,627 due to COVID slowdown in Taiwan.","Gross profit turned negative to $27,262 versus positive $317,664 in prior year.","Net loss to common shareholders was $2,349,727, up from $1,954,032 in Q2 2022.","VELDONA Pet launched in Taiwan; management targets $20M sales in 2024.","Cash and equivalents stood at $1.36M as of June 30, down from $1.85M at Dec. 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":77719.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273287,"accession_number":"0001654954-23-010410","cik":1014763,"company_name":"Ainos, Inc.","ticker":"AIMD","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Ainos signs co-development deal with Nisshinbo & Inabata for VOC sensing platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ainos will receive one-time upfront development fee plus per-unit fees for AI Nose tech.","Partnership targets telehealth, automotive, industrial, and environmental safety applications.","Agreement effective Aug 9, 2023 through Aug 31, 2026, with normal termination rights.","Ainos brings over 50 active/pending patents and deep-learning algorithm to the platform.","Nisshinbo outsources development; Inabata coordinates logistics between the parties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21822827.74683544,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-08-10T23:59:59+00:00|273287"}